For cancer treatment, ablation LOXL2 restores cancer cells RS, increases intratumoral CD8+ T cell infiltration, declines exhausted CD8+ T cells, thus reducing tumor burden and resensitizing anti-PD-L1 resistant lung cancer cells76,77. This evidence concerns the gene LOXL2 and lung cancer.